Abnormal Post-partum Glucose Metabolism After Gestational Diabetes Diagnosed Before or After 24 Weeks of Gestation
Abnormal Post-partum Glucose Metabolism After Gestational Diabetes Diagnosed Before or After 24 Weeks of Gestation
The main objective of the study is to estimate and compare the percentage of patients with
 abnormal glucose metabolism at 4-12 weeks postpartum between two groups: patients diagnosed
 with gestational diabetes before or after 24 weeks of pregnancy. Abnormal glucose metabolism
 is defined as type 2 diabetes, glucose intolerance or impaired fasting glucose.
The secondary objectives of this study are to compare between the two groups:

 A. the rate of type 2 diabetes only, glucose intolerance only, impaired fasting glucose only,
 and patients requiring insulin at 4-12 weeks postpartum

 B. rates of maternal and obstetric complications

 C. risk factors (age, body mass index, personal history of gestational diabetes or
 macrosomia, first degree family history of diabetes).

 D. For fasting glucose done before 24SA, we will calculate the optimal threshold for
 predicting abnormal glucose metabolism in the immediate postpartum period among women with
 gestational diabetes.
Inclusion Criteria:

 -  The patient must have given her informed and signed consent

 -  The patient must be insured or beneficiary of a health insurance plan

 -  The patient is available for 10 months of follow-up

 -  The patient is pregnant and consulting before 24 weeks of amenorrhea AND has at least
 one of the following risk factors: age > 35 years; body mass index > 25; family
 history of type 2 diabetes; history of gestational diabetes; history of macrosomia.

 -  The patient has a fasting blood glucose level >= 0.92 g/l before 24 weeks of
 amenorrhea OR a fasting blood glucose level < 0.92 g/l before 24 weeks of amenorrhea
 AND an abnormal oral glucose tolerance test (75 g of glucose) between 24 and 28 weeks
 of amenorrhea (normal values are set at T0 < 0.92 g/l; T60 < 1.80 g/l; T120 < 1.53
 g/l).

 Exclusion Criteria:

 -  The patient is participating in another study

 -  The patient is in an exclusion period determined by a previous study, with the
 exception of the following studies: Papillo PMA (RCB 2013-A00538-37), LXRs (RCB
 2009-A00968-49), GrossPath (RCB 2014-A01120-47), BAKRI (RCB 2013-A00914-41), OASIS II
 (RCB 2013-A00773-42), ElastoMAP (RCB 2013-A01148-37), ElastoDéclench (RCB
 2014-A00828-39) and UpSideDown (RCB 2014-A01921-46).

 -  The patient is under judicial protection, under tutorship or curatorship

 -  The patient refuses to sign the consent

 -  It is impossible to correctly inform the patient

 -  The patient cannot read French

 -  The patient has a known history of type 2 diabetes

 -  The patient is diagnosed with type 2 diabetes during pregnancy (fasting blood glucose
 level > 1.26 g/l)

 -  The patient has a contra-indication for a treatment necessary for this study

 -  The patient is taking chronic or intermittent oral or inhaled corticosteroids, or a β2
 agonist treatment for a previous disease or a disease discovered during pregnancy
 within one week preceding the fasting glucose or oral glucose tolerance test.